Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Peregrine Q1 Revenues Increases By 345%
Peregrine Pharmaceuticals has reported an increase in revenues by 345% to $6.7m for the first quarter of fiscal year 2010 ended July 31, 2009, compared to $1.5m for
Peregrine Pharmaceuticals has reported an increase in revenues by 345% to $6.7m for the first quarter of fiscal year 2010 ended July 31, 2009, compared to $1.5m for
Peplin has signed a merger agreement whereby LEO Pharma will acquire all outstanding securities of Peplin for approximately $287.5m in cash. In addition, LEO will provide Peplin with
Bristol-Myers Squibb has announced that FDA has accepted its submission of a biologic license application for belatacept, for filing and review. Belatacept is in ongoing phase III development
Commonwealth Biotechnologies (CBI) has executed an agreement to acquire all of the outstanding shares of GL Biochem (Shanghai) as well as GL Biochem (Danyang), GL Peptide (Binhai), and
Cornerstone Therapeutics has received the approval of the US Bankruptcy Court for the District of Massachusetts for its acquisition of the commercial rights to the antibiotic, Factive (gemifloxacin
Cytopia’s Investigational New Drug Application (IND) for CYT387 has passed the FDA review. CYT387 is a small-molecule oral JAK1/JAK2 kinase inhibitor designed to treat various haematological disorders. The
Shire has received FDA approval for INTUNIV (guanfacine) extended release tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years. INTUNIV,
Encap Drug Delivery has entered into a licensing agreement with The School of Pharmacy, University of London, for the use of their drug delivery system, Phloral. This coating
Acura Pharmaceuticals (Acura) and King Pharmaceuticals (King) have met with the FDA on September 2, 2009 to discuss the agency’s Complete Response Letter regarding the New Drug Application
Merck Sharp & Dohme (MSD) has launched SAFLUTAN (tafluprost) in the UK and Spain. Additional launches in other countries are expected over the next several months, pending regulatory